Milad Rouhimoghadam
Senior Scientist Abbvie
Milad Rouhimoghadam is a Senior Scientist at AbbVie. Prior to joining AbbVie, Milad was focused on targeted protein degradation platform and discovery of novel therapeutic strategies for cancer. At AbbVie, Milad is leading the NanoBRET Platform within the Targeted Protein Degradation group where he is developing cell-based NanoBRET assays to support the discovery of novel degraders, E3 ligases, and molecular glues, enabling high-throughput MOA profiling and mechanistic insights across programs.
Seminars
Thursday 29th January 2026
Platform for the Discovery of Molecular Glues
2:30 pm
- Lighting up molecular glue biology in real time – we developed a NanoBRET-powered high-throughput platform that directly visualizes E3 ligase–substrate interactions in live cells, transforming molecular glue discovery from serendipity to systematic science
- From mechanism to molecules – by capturing dynamic CRBN–CUL4A and DCAF15–CUL4A assemblies with sensitive NanoBRET proximity assays, this platform delivers both mechanistic insight and a scalable engine to uncover new degraders across the CRL family
- Expanding the degradable proteome – applying this approach, we identified novel glue candidates and validated CMC2 as a DCAF15-recruiting substrate for proof-of-concept degradation, demonstrating a powerful strategy to accelerate glue discovery and guide next-generation targeted protein degradation therapies
